# Decision: needs_human

Confidence: 0.91
Progress score: 4

## Rationale

Do not auto-continue to a new experiment yet. Iteration 0003 is structurally valid but only a weak pass, and its main scientific interpretation is ambiguous: the sampled-vs-soft advantage is not consistently supported by value error, the target-mean check is not against the recorded deterministic soft learner target, and the CliffWalking normalization makes policy success uninformative.

## Evidence

- 0003_result.json reports status completed with commands, artifacts, raw per-seed metrics, and CPU-only tabular scope.
- 0003_review.json allows auto-continue and reports no triggered failure criteria, but grades evidence quality as medium with verdict weak_pass.
- The strongest positive result is estimator variance: sampled conditional variance exceeds zero soft terminal-sampling variance in all 30 runs.
- Learning-performance evidence is mixed: mean final soft value error is 0.0821131 versus sampled value error 0.0815604, so soft is slightly worse on mean final value error.
- The reviewer flags soft value-error dominance as only 17/30 runs and only 4/10 at gamma 0.995.
- Bellman residual is the stronger dominance signal, with soft lower in 26/30 runs, but that is narrower than the broader value-error wording.
- The reviewer flags that sampled target means were compared to the sampled learner's conditional expected target, not the deterministic soft learner's recorded target.
- All evaluated policies have raw return -200 and success rate 0 under the chosen normalization.
- Current state records weak_pass_streak=2 and a blocked/resumed Pro checkpoint around 0004, so this is an appropriate human checkpoint.

## Risks

- Continuing automatically could compound an overclaim from 0003 into later experiments.
- Moving to auxiliary goals or function approximation now would be premature.
- Repeating CliffWalking without fixing reward normalization may keep producing degenerate policies and tie-heavy comparisons.
- A RiverSwim experiment may be the right next step, but choosing it now is a scope decision after ambiguous evidence.
